NCT01435525已完成不适用
Nexium Capsules Specific Clinical Experience Investigation Concerning Helicobacter Pylori Eradication
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 369
- 试验地点
- 1
- 主要终点
- Number of Adverse Drug Reactions
研究概览
简要总结
The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AMPC) + clarithromycin (CAM), or Nexium + AMPC + metronidazole (MNZ) in usual post-marketing use.
详细描述
Nexium capsules Specific Clinical Experience Investigation concerning Helicobacter pylori eradication
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •H.pylori negative at the time when the triple therapy is started
结局指标
主要结局
Number of Adverse Drug Reactions
时间窗: Period from the start of triple therapy to assessment of eradication, an expected average of 3 months
次要结局
- Rate of H.Pylori eradication(Period from the start of triple therapy to assessment of eradication, an expected average of 3 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Nexium Capsules Clinical Experience InvestigationGastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison SyndromeNCT01434485AstraZeneca3,691
已完成
不适用
Nexium Capsules Non-steroidal Anti-inflammatory Drug (NSAID) Specific Clinical Experience InvestigationGastric UlcerDuodenal UlcerNCT01562600AstraZeneca1,634
已完成
不适用
Nexium Capsules LDA Specific Clinical Experience InvestigationGastric UlcerDuodenal UlcerNCT01729182AstraZeneca2,363
已完成
不适用
Nexium Capsules RE Maintenance Specific Clinical Experience InvestigationRepeatedly Recurring EsophagitisRelapsing Reflux EsophagitisNCT01562639AstraZeneca647
已完成
不适用
Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical OutcomesReflux EsophagitisNCT02477475AstraZeneca1,595